We partner with companies and teams offering solutions to a broad range of national health security threats. DRIVe partnering approaches vary depending on the project. DRIVe has two main solicitations, our EZ BAA for awards under $749K and our BAA Special Instructions for more involved projects.

For additional details about the COVID-19 response please visit the CDC website


To support ongoing U.S. Government COVID-19 medical countermeasure development efforts, BARDA is pleased to open our EZ BAA program and seeks abstract submissions for select COVID-19 medical countermeasures only. Please see solicitation BAA-20-100-SOL-0002 for more information, and apply here.

How to Apply for the
EZ BAA and What to Expect

  1. Review the solicitation on beta.SAM.gov.*
  2. Request an account on the EZ BAA Portal.
  3. Once your account is active, complete the online abstract via the Portal.
  4. BARDA personnel will review your abstract as described in the solicitation.
  5. You'll receive an email notification within 30 days.
  6. *At this time we are only accepting responses related to SARS-CoV-2 programs in the following areas: 4.1D: Diagnostics, 4.3: COVID-19 Vaccines, and 4.4: Advanced Manufacturing Technologies.

Thank you for your interest; submissions closed on May 28th. Stay tuned for future opportunities.

How to Apply for
BAA Special Instructions and What to Expect

Which Solicitation Should You Submit To?

BAA Special Instructions

  • Considering awards of up to $8M*
  • Mature Proposals
  • Areas of Interest (AoI): ENACT and Solving Sepsis
  • White Paper Submission Required
  • Two-Stage Review Process


  • Awards of up to $749K*
  • Emerging Disruptive Ideas
  • AoIs: ENACT, Solving Sepsis, and Other Disruptive Innovations
  • Simplified Abstract
  • 30-120 Day Review Target

*Award amounts may differ depending on award structure and/or availability of funding

Partnering Approaches

Driv-X icon

DriVe X

DRIVe-X is our hyper-focused innovation development program, using non-dilutive funding to address national health security threats. If you're interested in partnering with us, please review our EZ BAA or BAA Special Instructions. Additional partnering opportunities will follow. For more information, please see the full beta.sam.gov EZ BAA announcement or BAA Special Instructions.

hand with leaf icon


DRIVe Launch establishes a bilateral partnership with a non-profit third-party entity with the potential for the entity to take equity positions in companies and/or technologies. DRIVe Launch will address gaps which require innovative and entrepreneurial approaches that may not be considered under traditional medical countermeasure development.



DRIVe Ventures will work with corporate venture capital partners to invest in promising products, driving them to the marketplace to transform and enhance national health security. Learn more.



DRIVe is decentralizing innovation across the country. The DRIVe Accelerator Network is working with regional accelerators to identify promising innovation and provide wraparound technical and business development support services. Learn more.

DRIVe (Division of Research, Innovation, and Ventures) was established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR), within the United States Department of Health and Human Services (HHS).